ArticleNature microbiology2023
Host range, transmissibility and antigenicity of a pangolin coronavirus.
Article in Nature microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 33 citations in OpenAlex.
- Genetic diversity of pangolin coronaviruses reveals a key immuno-evasive substitution at spike residue 519.Journal of virology · 2026Article
- COVID-19 vaccination induces cross-neutralisation of sarbecoviruses related to SARS-CoV-2.NPJ vaccines · 2026Article
- A system capable of verifiably and privately screening global DNA synthesis.National science review · 2026Article
- Extra gene coding capacity of SARS-CoV-2 provides a virus engineering platform for in vitro and in vivo applications.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Article
- Programmable antibody-based chimeric entry receptors for sarbecoviruses.Communications biology · 2026Article
- Clues to Long COVID Linked to Virulence and Infectivity Found in Shell Proteins.Advances in respiratory medicine · 2026Review
- A neutralizing human antibody induces movement of the HCoV-229E receptor binding domain.Communications biology · 2025Article
- From zoonotic spillover to endemicity: the broad determinants of human coronavirus tropism.mBio · 2025Review
- Bat sarbecovirus WIV1-CoV bears an adaptive mutation that alters spike dynamics and enhances ACE2 binding.PLoS pathogens · 2025Article
- Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates.Science translational medicine · 2025Article
- The World Needs a PEPP Policy that Addresses Biosafety Loopholes Highlighted by the COVID-19 Pandemic.Applied biosafety : journal of the American Biological Safety Association · 2025Article
- Article
- Comparative analysis of gut microbiota and metabolome in captive Chinese and Malayan pangolins.Frontiers in microbiology · 2025Article
- A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice.Cell host & microbe · 2024Article
- An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo.Cell reports · 2024Article
- Animal models of Long Covid: A hit-and-run disease.Science translational medicine · 2024Review
- Distinct pathways for evolution of enhanced receptor binding and cell entry in SARS-like bat coronaviruses.PLoS pathogens · 2024Article
- Molecular determinants of cross-species transmission in emerging viral infections.Microbiology and molecular biology reviews : MMBR · 2024Review
- Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination.Cell reports. Medicine · 2024Article
Corrections and comments
- Commented on by
Authors and funding
25 authors at 4 institutions in 1 country.
Funding
Abstract
The pathogenic and cross-species transmission potential of SARS-CoV-2-related coronaviruses (CoVs) remain poorly characterized. Here we recovered a wild-type pangolin (Pg) CoV GD strain including derivatives encoding reporter genes using reverse genetics. In primary human cells, PgCoV replicated efficiently but with reduced fitness and showed less efficient transmission via airborne route compared with SARS-CoV-2 in hamsters. PgCoV was potently inhibited by US Food and Drug Administration approved drugs, and neutralized by COVID-19 patient sera and SARS-CoV-2 therapeutic antibodies in vitro. A pan-Sarbecovirus antibody and SARS-CoV-2 S2P recombinant protein vaccine protected BALB/c mice from PgCoV infection. In K18-hACE2 mice, PgCoV infection caused severe clinical disease, but mice were protected by a SARS-CoV-2 human antibody. Efficient PgCoV replication in primary human cells and hACE2 mice, coupled with a capacity for airborne spread, highlights an emergence potential. However, low competitive fitness, pre-immune humans and the benefit of COVID-19 countermeasures should impede its ability to spread globally in human populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.